Allergy Therapeutics Stock Value
Allergy Therapeutics Company Info
EPS Growth 5Y
-19,73%
Market Cap
£0,65 B
Long-Term Debt
£0,05 B
Quarterly earnings
06/27/2026 (E)
Dividend
£0,00
Dividend Yield
0,00%
Founded
1998
Industry
Country
Website
ISIN Number
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
£0,13
30%
Last Update: 04/01/2026
Analysts: 1
Highest Price Target £0,13
Average Price Target £0,13
Lowest Price Target £0,13
In the last five quarters, Allergy Therapeutics’s Price Target has risen from £0,13 to £0,13 - a 0,00% increase. One analysts predict that Allergy Therapeutics’s share price will increase in the coming year, reaching £0,13. This would represent an increase of 30,00%.
Top growth stocks in the health care sector (5Y.)
What does Allergy Therapeutics do?
Allergy Therapeutics plc is a pioneering biopharmaceutical company focused on the development and commercialization of innovative allergy immunotherapy products. The company primarily aims to transform patients' lives through a strong commitment to advancing treatments in immunology. With specialized expertise, a robust product pipeline, and a focus on high-quality standards, Allergy Therapeutics is dedicated to becoming a leader in the allergy treatment market.
Business Segments
The Company o...
Allergy Therapeutics Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Industries:**
- Pharmaceutical products
- Biotechnology
**TOP 3 Markets:**
1. **Germany:** approximately 40%
2. **United Kingdom:** approximately 25%
3. **Spain:** approximately 15%
Allergy Therapeutics plc generates the majority of its revenue from the manufacturing and distribution of allergy...
At which locations are the company’s products manufactured?
**Production Site:** Worthing, West Sussex, United Kingdom
Allergy Therapeutics plc mainly produces its products in Worthing, West Sussex. The location in the United Kingdom is the company's central production center, where it manufactures its allergy immunotherapy products. This strategic loc...
What strategy does Allergy Therapeutics pursue for future growth?
**Revenue Growth:** Estimated 8-10% annually (based on historical data and market trends until 2023)
**Research and Development:** Increase in R&D spending by 15% (last year)
Allergy Therapeutics plc pursues a growth strategy strongly focused on innovation and research. The company invests sig...
Which raw materials are imported and from which countries?
**Main raw materials:** Allergen extracts, adjuvants for vaccines
**Countries of origin:** USA, Germany, France
Allergy Therapeutics plc specializes in the development and production of allergy vaccines. The main raw materials imported by the company are allergen extracts needed for the production...
How strong is the company’s competitive advantage?
**Market share in the allergy market:** Estimated at 5-7% (2026)
**Research and Development (R&D) expenses:** 20% of revenue (2025)
Allergy Therapeutics plc has a moderate competitive advantage in the allergy market, supported by their specialized products and continuous investments in researc...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Estimate: approx. 40% (2026)
**Insider Buys/Sells:** No specific data available for 2026
The institutional investor share in Allergy Therapeutics plc is estimated to be around 40%. This is typical for companies in the biotechnology industry, where institutional i...
What percentage market share does Allergy Therapeutics have?
**Market share of Allergy Therapeutics plc:** 5% (estimated for 2026)
**Main competitors and their market shares:**
1. **ALK-Abelló A/S:** 25%
2. **Stallergenes Greer:** 20%
3. **HAL Allergy Group:** 15%
4. **Leti Pharma:** 10%
5. **Allergy Therapeutics plc:** 5%
6. **Circassia Pharmaceuticals:** 5...
Is Allergy Therapeutics stock currently a good investment?
**Revenue Growth:** 8% (2025)
**Research and Development Expenses:** 12% of Revenue (2025)
**Market Share in Europe:** 20% (2025)
Allergy Therapeutics plc has experienced solid revenue growth of 8% in recent years, attributed to strong demand for its products and effective market penetration. The c...
Does Allergy Therapeutics pay a dividend – and how reliable is the payout?
**Dividend payment:** No dividend (as of 2026)
Allergy Therapeutics plc has not paid any dividends in recent years. The company focuses on reinvesting its profits into research and development to expand its product pipeline and seize new market opportunities. This is typical for companies in the bi...
